[64Cu]FBP8 PET for Early Detection of Intracardiac Thrombus in Amyloid Cardiomyopathy

Recruiting now · Phase 3

Conditions studied: Cardiac Amyloidosis

In brief

The primary goal of this pilot study is to determine whether \[64Cu\]FBP8, a novel fibrin-binding positron emission tomography (PET) probe, can identify intracardiac thrombi when paired with simultaneous hybrid cardiac PET/MRI in twenty (20) individuals with transthyretin or light chain cardiac amyloidosis and atrial fibrillation (AF) or atrial flutter (AF). The primary hypothesis of this study is that \[64Cu\]FBP8 PET/MRI can identify intracardiac thrombi in \>90% of subjects with confirmed intracardiac thrombi based on transesophageal echocardiogram (TEE). In secondary analyses, the investigators will seek to determine associations between intracardiac thrombi and left atrial function and left ventricular amyloid burden.

Key facts

Study ID

NCT07560306

Run by

Brigham and Women's Hospital

People needed

20

Starts

2026-07-07

Expected to finish

2027-03-30

Last updated by the study team

2026-07-21

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Have the ability to give written informed consent;
• History of amyloid cardiomyopathy (ATTR-CM or AL-CM);
• History of AF or AFL;
• Retrospective enrollment: TEE to evaluate LAA within the previous 14 days, provided the anticoagulation regimen the patient is on is not changed after the TEE. If a patient has a negative TEE and continues the same stable anticoagulation regimen, then it is unlikely that a new thrombus will develop in the LAA within the next 14 days. Likewise, if a patient not taking any anticoagulation has a thrombus in the LAA, then it is unlikely that this thrombus will resolve spontaneously in the next 14 days if the patient remains off anticoagulation. If the TEE leads to a change being made in the anticoagulation regimen (started/stopped/dose modified), then a time window of 72 hours from the TEE to PET/MR imaging will be used. This scheme will ensure that the TEE can serve as an accurate gold standard;
• Prospective: TEE to evaluate LAA thrombus scheduled in upcoming 14 days;

You may not qualify if…

• Electrical implants such as cardiac pacemaker/defibrillator, perfusion pump, direct brain stimulator;
• Pregnancy or breastfeeding (a negative quantitative serum or urine hCG pregnancy test is required for females having child-bearing potential before the subject can participate);
• Claustrophobia;
• Subjects will be excluded if research-related radiation exposure exceeds current Radiology Department guidelines (i.e. 50 mSv in the prior 12 months);
• Unable to lie comfortably on a bed inside the PET/MR scanner;
• Subjects under direct or indirect (i.e., same department as PIs) supervision of the principal investigator;
• Body weight over the weight limit for the moving table (> 300 lbs for the MR table);
• Metallic or electric implants contraindicated for PET/MR scanning;
• Stroke, myocardial infarction, cardiac or major surgery within the last 3 months;
• History of LAA ligation/exclusion or presence of a LAA occlusion device;
• History of syncope within the last 6 weeks;
• Heart rate persistently >120 bpm or persistently <50 bpm;
• Daytime pauses >3 seconds;
• Lack of a prior transthoracic echocardiogram within the previous 6 months;
• Does not have the ability to give written informed consent;
• Determined by the investigator(s) to be clinically unsuitable for the study (e.g., based on screening visit and/or during study procedures);

Where it is running

• Brigham and Women's Hospital — Boston, Massachusetts, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.